Zafir Hawa, MD
Interventional Cardiology · North Kansas City, MONPI 1235102302
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $500 of the $589 with a category attached, or 84.9%. 5 manufacturers reported payments, led by Abbott at 56.9% of the total. 2025 is the largest year on record at $221, 2.2 times the $101 reported in 2019. That places this record below the midpoint for interventional cardiology clinicians in MO, where the typical reported total is $10,448.
Across 24 payments — averaging $24.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$335
- Edwards Lifesciences$123
- Medtronic$101
- AbbVie$18
- Boston Scientific$12
Across 187 payments — averaging $3420.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$341K
- Novartis$162K
- Boehringer Ingelheim International GmbH$57K
- Boehringer Ingelheim Pharma GmbH & Co.kg$39K
- Janssen Research & Development, LLC$18K
- Boston Scientific$15K
- plus $8K from 1 others
What the payments were for
- Grants$8915%
- Food & beverage$50085%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 14 | $335 |
| Edwards Lifesciences | 6 | $123 |
| Medtronic(2 entities) | 2 | $101 |
| AbbVie | 1 | $18 |
| Boston Scientific | 1 | $12 |
How this compares
$589 in reported general payments places this provider in the 5th percentile of 182 interventional cardiology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 263 | $286,386 |
| EntrestoSacubitril/Valsartan | 121 | $118,447 |
| Repatha SureclickEvolocumab | 106 | $113,568 |
| XareltoRivaroxaban | 45 | $46,521 |
| JardianceEmpagliflozin | 42 | $44,601 |
| Praluent PenAlirocumab | 20 | $18,613 |
| Metoprolol Succinate | 657 | $7,684 |
| Atorvastatin Calcium | 530 | $5,625 |
| Clonidine | 18 | $5,537 |
| Ranolazine ErRanolazine | 40 | $5,295 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 199 | $4,655 |
| Carvedilol | 464 | $4,215 |
| Rosuvastatin Calcium | 255 | $3,506 |
| Losartan Potassium | 304 | $2,910 |
| Midodrine Hcl | 29 | $2,620 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in North Kansas City
- Joshua StolkerWashington$1.2M
- John LasalaSaint Louis$936K
- Harvey SerotaSaint Louis$752K
- Jasvindar SinghSaint Louis$696K
- Gerald MancusoKansas City$402K
- James GranthamKansas City$357K
- Matthew BunteKansas City$242K
- Alan ZajariasSaint Louis$203K
- Anish ThomasSaint Louis$171K
- Gus TheodosSaint Louis$165K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.